GlassScriptPhysician profile
Manik Mehra
NPI 1760745970
$2,510.71
in general payments reported to CMS, 2019-2025
31 companies · $409 in 2025
The $409 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.43 · 2021: $35.68 · 2022: $764 · 2023: $485 · 2024: $789 · 2025: $409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $512.76 | 2022-2025 | Tezspire, Farxiga, Breztri |
| Abbvie INC. | $391.90 | 2022-2025 | |
| Lilly USA, LLC | $237.32 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $197.95 | 2022-2024 | Caplyta |
| Pfizer INC. | $118.30 | 2024-2025 | |
| Abbott Laboratories | $114.49 | 2022-2025 | Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $107.31 | 2024-2025 | Rexulti |
| Lundbeck LLC | $93.88 | 2022-2025 | Rexulti |
| Dexcom, INC. | $83.49 | 2024-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $80.16 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $74.29 | 2022-2025 | |
| Axsome Therapeutics, INC. | $37.22 | 2022-2023 | Auvelity |
| Myriad Genetic Laboratories, INC. | $35.68 | 2021 | |
| Verona Pharma, INC. | $35.65 | 2025 | Ohtuvayre |
| Medtronic, INC. | $34.13 | 2022-2024 | Minimed 780g |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $32.76 | 2023 | Trogarzo, Egrifta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.61 | 2022-2023 | Jardiance |
| Mylan Specialty L.P. | $28.33 | 2022 | |
| Glaxosmithkline, LLC. | $28.22 | 2024 | Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $27.43 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.42 | 2022 | |
| Amgen INC. | $27.36 | 2022-2023 | Otezla, Repatha |
| Eisai INC. | $19.59 | 2024 | |
| Boston Scientific Corporation | $17.68 | 2025 | Watchman Access System |
| Radius Health, INC. | $17.54 | 2023 | Tymlos |
| Merck Sharp & Dohme LLC | $17.49 | 2024 | Gardasil 9, Vaxelis, Gardasil |
| Janssen Pharmaceuticals, INC | $17.41 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.81 | 2022 | |
| Tonix Medicines, INC. | $16.20 | 2025 | Tonmya |
| Electromed, INC. | $15.04 | 2025 | Smartvest |
| Phathom Pharmaceuticals, INC. | $14.29 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manik Mehra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.